Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pioglitazone/metformin.

Emma D Deeks1, Lesley J Scott

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 17, 2006
PubMed
Summary
This summary is machine-generated.

Fixed-dose pioglitazone/metformin tablets offer improved glycemic and lipid control for type 2 diabetes patients. This combination therapy demonstrates superior lipid management compared to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022
Same author

Asciminib: First Approval.

Drugs·2022
Same author

Chiglitazar: First Approval.

Drugs·2021
Same author

Atogepant: First Approval.

Drugs·2021
Same author

Abrocitinib: First Approval.

Drugs·2021
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) affects millions globally, necessitating effective glycemic and lipid management.
  • Metformin and pioglitazone are established treatments for T2DM, often used in combination.
  • Fixed-dose combination tablets simplify treatment regimens for patients with inadequate glycemic control on monotherapy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a fixed-dose pioglitazone/metformin combination tablet.
  • To compare the combination therapy's effects on glycemic and lipid control against other treatment regimens.
  • To establish bioequivalence between the fixed-dose tablet and coadministered separate agents.

Main Methods:

  • Bioequivalence studies assessing absorption and bioavailability.

Related Experiment Videos

  • Clinical trials comparing pioglitazone/metformin to metformin/placebo over 16 weeks.
  • Longer-term trials (12 months to 3.5 years) comparing pioglitazone/metformin with rosiglitazone/metformin and sulfonylurea/metformin combinations.

    • Main Results:

    • Pioglitazone/metformin significantly improved glycemic and lipid control compared to metformin/placebo.
    • The combination showed comparable antihyperglycemic efficacy to rosiglitazone/metformin but superior lipid control.
    • Compared to sulfonylurea/metformin, pioglitazone/metformin offered similar glycemic control with better triglyceride and HDL-cholesterol levels.
    • The fixed-dose tablet demonstrated bioequivalence to separate agents.

    Conclusions:

    • Fixed-dose pioglitazone/metformin is an effective treatment option for T2DM patients with inadequate glycemic control.
    • This combination therapy provides significant benefits in both glycemic and lipid management.
    • The drug is generally well-tolerated, with an adverse event profile similar to metformin monotherapy.